In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Apixaban successfully resolved left atrial appendage thrombus in patients with end stage renal disease with dialysis

Session Poster Session 3 - Clinical Cases

Speaker Yae Min Park

Congress : Heart Failure 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Atrial Fibrillation - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P2053

Authors : YM Park (Incheon,KR), MS Cha (Incheon,KR), J Moon (Incheon,KR), W-J Chung (Incheon,KR), M-S Shin (Incheon,KR), IS Choi (Incheon,KR)


YM Park1 , MS Cha1 , J Moon1 , W-J Chung1 , M-S Shin1 , IS Choi1 , 1Gil Hospital , Gachon University of Medicine & Science - Incheon - Korea Republic of ,


Introduction: We report a patient requiring dialysis with left atrial appendage (LAA) thrombus which was successfully resolved with apixaban

Methods: N/A

Results: A 62-year-old female who had a history of end stage renal disease (ESRD) with dialysis was referred to our electrophysiology department due to paroxysmal atrial fibrillation (AF). Anticoagulation therapy with warfarin was started, because her CHADS2-VASc score was 4 (hypertension, diabetes, congestive heart failure, and female gender) as well as amiodarone for rhythm control. Trans-esophageal echocardiography was performed which revealed thrombus in left atrial appendage (LAA). Tachycardia-bradycardia syndrome was documented, therefore, catheter ablation was planned. Follow up TEE identified still remained thrombus despite approximately 1 year of anticoagulation therapy with warfarin. Therefore, warfarin was switched to the direct factor Xa inhibitor, apixaban 5mg bid. After four months of apixaban treatment, TEE revealed complete resolution of LAA thrombus. Finally, catheter ablation was performed without any complication and the patient has been in sinus rhythm thereafter under continued anticoagulant treatment with apixaban. Neither thromboembolic nor bleeding events did not occur during follow up for > 9 months.

Conclusion: Factor Xa inhibitor, apixaban, can successfully and safely resolve the LAA thrombus refractory to warfarin in patients with ESRD requiring dialysis.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are